Frazier Life Sciences Acquisition Corp. II
Cha Albert (Chief Executive Officer) purchased 300,000 indirectly-held shares of Frazier Life Sciences Acquisition Corp. II (FLSC) at $10.00 ($3.00M total) on 2026-10-15. Filed jointly with Frazier Life Sciences Holdings II LLC (10% owner), Frazier Life Sciences Public Fund, L.P. (10% owner), FHMLSP, L.P. (10% owner) and FHMLSP, L.L.C. (10% owner).
Frazier Life Sciences Acquisition Corp. II (FLSC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Frazier Life Sciences Acquisition Corp. II Announces Pricing of $75,000,000 Initial Public Offering Palo Alto, CA, October 13, 2026 – Frazier Life Sciences Acquisition Corp. II (the “Company”), a special purpose acquisition company, announced today that it priced its
Frazier Life Sciences Acquisition Corp. II raised $75m in its IPO, issuing 7.5m shares at $10 each. The SPAC began trading on Nasdaq under the ticker FLSC. The company, led by CEO Albert Cha, aims to merge with a biotechnology business. Jefferies managed the offering, which was approved by the SEC.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning FLSC (Frazier Life Sciences Acquisition Corp. II). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent FLSC coverage spans insider activity, corporate actions and ipo.
In the last 30 days, FLSC insiders filed 1 SEC Form 4 transaction — 1 purchase ($3.0M) and no sales. The most active reporter was Cha Albert, Chief Executive Officer, with 1 filing.
The filing is a fresh insider open-market purchase, which can be read as confidence but is not a fundamental change by itself.
Newly disclosed IPO pricing and expected close date create immediate float and liquidity expectations for FLSC, with near-term trading focus on first-day positioning.
Newly listed SPAC with fresh capital and a stated biotech acquisition mandate, creating near-term trading interest around IPO allocation and early liquidity.
AlphAI scores every news story that mentions FLSC with an AI model for sentiment and relevance, and aggregates insider trades from Frazier Life Sciences Acquisition Corp. II's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cha Albert (Chief Executive Officer) purchased 300,000 indirectly-held shares of Frazier Life Sciences Acquisition Corp. II (FLSC) at $10.00 ($3.00M total) on 2026-10-15. Filed jointly with Frazier Life Sciences Holdings II LLC (10% owner), Frazier Life Sciences Public Fund, L.P. (10% owner), FHMLSP, L.P. (10% owner) and FHMLSP, L.L.C. (10% owner).
2 min readFrazier Life Sciences Acquisition Corp. II (FLSC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Frazier Life Sciences Acquisition Corp. II Announces Pricing of $75,000,000 Initial Public Offering Palo Alto, CA, October 13, 2026 – Frazier Life Sciences Acquisition Corp. II (the “Company”), a special purpose acquisition company, announced today that it priced its
4 min readFrazier Life Sciences Acquisition Corp. II raised $75m in its IPO, issuing 7.5m shares at $10 each. The SPAC began trading on Nasdaq under the ticker FLSC. The company, led by CEO Albert Cha, aims to merge with a biotechnology business. Jefferies managed the offering, which was approved by the SEC.
2 min read